Cargando…
Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study
BACKGROUND: Circulating tumor DNA (ctDNA) is an approved noninvasive biomarker to test for the presence of EGFR mutations at diagnosis or recurrence of lung cancer. However, studies evaluating ctDNA as a noninvasive “real-time” biomarker to provide prognostic and predictive information in treatment...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189949/ https://www.ncbi.nlm.nih.gov/pubmed/28027313 http://dx.doi.org/10.1371/journal.pmed.1002199 |
_version_ | 1782487320440602624 |
---|---|
author | Pécuchet, Nicolas Zonta, Eleonora Didelot, Audrey Combe, Pierre Thibault, Constance Gibault, Laure Lours, Camille Rozenholc, Yves Taly, Valérie Laurent-Puig, Pierre Blons, Hélène Fabre, Elizabeth |
author_facet | Pécuchet, Nicolas Zonta, Eleonora Didelot, Audrey Combe, Pierre Thibault, Constance Gibault, Laure Lours, Camille Rozenholc, Yves Taly, Valérie Laurent-Puig, Pierre Blons, Hélène Fabre, Elizabeth |
author_sort | Pécuchet, Nicolas |
collection | PubMed |
description | BACKGROUND: Circulating tumor DNA (ctDNA) is an approved noninvasive biomarker to test for the presence of EGFR mutations at diagnosis or recurrence of lung cancer. However, studies evaluating ctDNA as a noninvasive “real-time” biomarker to provide prognostic and predictive information in treatment monitoring have given inconsistent results, mainly due to methodological differences. We have recently validated a next-generation sequencing (NGS) approach to detect ctDNA. Using this new approach, we evaluated the clinical usefulness of ctDNA monitoring in a prospective observational series of patients with non-small cell lung cancer (NSCLC). METHODS AND FINDINGS: We recruited 124 patients with newly diagnosed advanced NSCLC for ctDNA monitoring. The primary objective was to analyze the prognostic value of baseline ctDNA on overall survival. ctDNA was assessed by ultra-deep targeted NGS using our dedicated variant caller algorithm. Common mutations were validated by digital PCR. Out of the 109 patients with at least one follow-up marker mutation, plasma samples were contributive at baseline (n = 105), at first evaluation (n = 85), and at tumor progression (n = 66). We found that the presence of ctDNA at baseline was an independent marker of poor prognosis, with a median overall survival of 13.6 versus 21.5 mo (adjusted hazard ratio [HR] 1.82, 95% CI 1.01–3.55, p = 0.045) and a median progression-free survival of 4.9 versus 10.4 mo (adjusted HR 2.14, 95% CI 1.30–3.67, p = 0.002). It was also related to the presence of bone and liver metastasis. At first evaluation (E1) after treatment initiation, residual ctDNA was an early predictor of treatment benefit as judged by best radiological response and progression-free survival. Finally, negative ctDNA at E1 was associated with overall survival independently of Response Evaluation Criteria in Solid Tumors (RECIST) (HR 3.27, 95% CI 1.66–6.40, p < 0.001). Study population heterogeneity, over-representation of EGFR-mutated patients, and heterogeneous treatment types might limit the conclusions of this study, which require future validation in independent populations. CONCLUSIONS: In this study of patients with newly diagnosed NSCLC, we found that ctDNA detection using targeted NGS was associated with poor prognosis. The heterogeneity of lung cancer molecular alterations, particularly at time of progression, impairs the ability of individual gene testing to accurately detect ctDNA in unselected patients. Further investigations are needed to evaluate the clinical impact of earlier evaluation times at 1 or 2 wk. Supporting clinical decisions, such as early treatment switching based on ctDNA positivity at first evaluation, will require dedicated interventional studies. |
format | Online Article Text |
id | pubmed-5189949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-51899492017-01-19 Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study Pécuchet, Nicolas Zonta, Eleonora Didelot, Audrey Combe, Pierre Thibault, Constance Gibault, Laure Lours, Camille Rozenholc, Yves Taly, Valérie Laurent-Puig, Pierre Blons, Hélène Fabre, Elizabeth PLoS Med Research Article BACKGROUND: Circulating tumor DNA (ctDNA) is an approved noninvasive biomarker to test for the presence of EGFR mutations at diagnosis or recurrence of lung cancer. However, studies evaluating ctDNA as a noninvasive “real-time” biomarker to provide prognostic and predictive information in treatment monitoring have given inconsistent results, mainly due to methodological differences. We have recently validated a next-generation sequencing (NGS) approach to detect ctDNA. Using this new approach, we evaluated the clinical usefulness of ctDNA monitoring in a prospective observational series of patients with non-small cell lung cancer (NSCLC). METHODS AND FINDINGS: We recruited 124 patients with newly diagnosed advanced NSCLC for ctDNA monitoring. The primary objective was to analyze the prognostic value of baseline ctDNA on overall survival. ctDNA was assessed by ultra-deep targeted NGS using our dedicated variant caller algorithm. Common mutations were validated by digital PCR. Out of the 109 patients with at least one follow-up marker mutation, plasma samples were contributive at baseline (n = 105), at first evaluation (n = 85), and at tumor progression (n = 66). We found that the presence of ctDNA at baseline was an independent marker of poor prognosis, with a median overall survival of 13.6 versus 21.5 mo (adjusted hazard ratio [HR] 1.82, 95% CI 1.01–3.55, p = 0.045) and a median progression-free survival of 4.9 versus 10.4 mo (adjusted HR 2.14, 95% CI 1.30–3.67, p = 0.002). It was also related to the presence of bone and liver metastasis. At first evaluation (E1) after treatment initiation, residual ctDNA was an early predictor of treatment benefit as judged by best radiological response and progression-free survival. Finally, negative ctDNA at E1 was associated with overall survival independently of Response Evaluation Criteria in Solid Tumors (RECIST) (HR 3.27, 95% CI 1.66–6.40, p < 0.001). Study population heterogeneity, over-representation of EGFR-mutated patients, and heterogeneous treatment types might limit the conclusions of this study, which require future validation in independent populations. CONCLUSIONS: In this study of patients with newly diagnosed NSCLC, we found that ctDNA detection using targeted NGS was associated with poor prognosis. The heterogeneity of lung cancer molecular alterations, particularly at time of progression, impairs the ability of individual gene testing to accurately detect ctDNA in unselected patients. Further investigations are needed to evaluate the clinical impact of earlier evaluation times at 1 or 2 wk. Supporting clinical decisions, such as early treatment switching based on ctDNA positivity at first evaluation, will require dedicated interventional studies. Public Library of Science 2016-12-27 /pmc/articles/PMC5189949/ /pubmed/28027313 http://dx.doi.org/10.1371/journal.pmed.1002199 Text en © 2016 Pécuchet et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Pécuchet, Nicolas Zonta, Eleonora Didelot, Audrey Combe, Pierre Thibault, Constance Gibault, Laure Lours, Camille Rozenholc, Yves Taly, Valérie Laurent-Puig, Pierre Blons, Hélène Fabre, Elizabeth Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study |
title | Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study |
title_full | Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study |
title_fullStr | Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study |
title_full_unstemmed | Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study |
title_short | Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study |
title_sort | base-position error rate analysis of next-generation sequencing applied to circulating tumor dna in non-small cell lung cancer: a prospective study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189949/ https://www.ncbi.nlm.nih.gov/pubmed/28027313 http://dx.doi.org/10.1371/journal.pmed.1002199 |
work_keys_str_mv | AT pecuchetnicolas basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT zontaeleonora basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT didelotaudrey basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT combepierre basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT thibaultconstance basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT gibaultlaure basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT lourscamille basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT rozenholcyves basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT talyvalerie basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT laurentpuigpierre basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT blonshelene basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy AT fabreelizabeth basepositionerrorrateanalysisofnextgenerationsequencingappliedtocirculatingtumordnainnonsmallcelllungcanceraprospectivestudy |